Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
References (30)
Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection
Am J Med.
(1996)- et al.
Current issues in NSAID therapy
Prim Care
(1990) - et al.
Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
Gastroenterology
(1996) - et al.
Prostaglandin endoperoxide H synthases-1 and -2
Adv Immunol
(1996) Effects of nonsteroidal anti-inflammatory therapy on platelets
Am J Med
(1999)Future trends in the development of safer nonsteroidal anti-inflammatory drugs
Am J Med
(1998)- et al.
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
Mayo Clin Proc.
(1999) - et al.
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
Lancet
(1999) - et al.
Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis
Curr Opin Rheumatol
(1994) - et al.
Cyclooxygenase in biology and disease
FASEB J
(1998)
Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
Arch Intern Med
Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration
Inflamm Res
Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data
Scand J Rheumatol Suppl.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
Proc Natl Acad Sci USA
COX-1 and COX-2 tissue expression: Implications and predictions
J Rheumatol
Cited by (63)
Therapeutics on the clock: Circadian medicine in the treatment of chronic inflammatory diseases
2020, Biochemical PharmacologyCelecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection
2016, Journal of Controlled ReleaseCitation Excerpt :Since serine proteases are present in synovial fluid and a key component of the inflammatory response, drug release from a PEA based DDS is potentially reactive to the disease process in inflammation related conditions such as OA [12,13]. A candidate anti-inflammatory drug to incorporate into PEA microspheres is the COX-2 inhibitor celecoxib, which is an anti-inflammatory drug that has been shown to be an effective analgesic for OA related pain [14]. Celecoxib, when administered systemically, has been reported to raise the risk for cardiovascular events, however incorporating the drug in a PEA based DDS for intra-articular administration can circumvent these side effects [15].
Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials
2010, Osteoarthritis and CartilageCitation Excerpt :The results of the article selection process are reported in Fig. 1. From the 343 articles identified, 33 articles were included14–46. Flare design was used in 27/33 (82%) studies.
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
2008, Seminars in Arthritis and RheumatismCitation Excerpt :Similar results were found when the American Pain Society Pain Measure Questionnaire was used as the outcome measure (14). Other studies in patients with OA of the knee found that celecoxib 100 mg twice daily and diclofenac 50 mg thrice daily had similar efficacy (15) and that celecoxib efficacy was not significantly different whether dosed at 100 mg twice daily or 200 mg once daily (both doses were superior to placebo) (16). Hence, the usual clinical practice is to begin therapy with 200 mg once daily; indeed, this is the most frequently prescribed dose in patients with OA (17).
Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials
2007, European Journal of PainCitation Excerpt :Subgroup analyses showed a reduction of heterogeneity to non-significance (p ⩾ 0.3) for pain data in both subgroups (Q-value 13.8 and 10.8 for biased and unbiased trials, respectively). Maximum efficacy for the subgroup of 14 trials (Weaver et al., 1995; Makarowski et al., 1996; Simon et al., 1998; Bensen et al., 1999; Zhao et al., 1999a; Ehrich et al., 2001; McKenna et al., 2001a,b; Williams et al., 2001; Gottesdiener et al., 2002; Case et al., 2003; Gibofsky et al., 2003; Kivitz et al., 2004; Detrembleur et al., 2005) which used this responder criterion was significantly higher (p < 0.001) at 11.8 mm [95% CI 10.5–13.1] on VAS, than for the 12 other trials (Lee et al., 1985; Williams et al., 1989; Dore et al., 1995; Schnitzer et al., 1995; Fleischmann et al., 1997; Lund et al., 1998; Scott et al., 2000; Uzun et al., 2001; Kivitz et al., 2002; Tannenbaum et al., 2004; Lehmann et al., 2005; Sheldon et al., 2005) where maximum efficacy was 7.9 mm [95% CI 6.9 to 8.9] on VAS. This difference persisted over time and was highly significant at secondary outcome measurements too (p < 0.001).